PRI-101 could become first disease-modifying Parkinson’s drug
Biotechnology company Priavoid GmbH has announced proof-of-concept data for PRI-101, an orally available peptide drug targeting neurodegeneration. Preclinical studies demonstrate the experimental therapy reduces toxic α-synuclein aggregates across multiple Parkinson’s disease models, with evidence of blood-brain barrier penetration and improved survival outcomes.
Already a member? Sign in
